Literature DB >> 20923768

Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

Janis Noonan1, Riffat Tanveer, Allan Klompas, Aoife Gowran, Joanne McKiernan, Veronica A Campbell.   

Abstract

Neuronal cell loss underlies the pathological decline in cognition and memory associated with Alzheimer disease (AD). Recently, targeting the endocannabinoid system in AD has emerged as a promising new approach to treatment. Studies have identified neuroprotective roles for endocannabinoids against key pathological events in the AD brain, including cell death by apoptosis. Elucidation of the apoptotic pathway evoked by β-amyloid (Aβ) is thus important for the development of therapeutic strategies that can thwart Aβ toxicity and preserve cell viability. We have previously reported that lysosomal membrane permeabilization plays a distinct role in the apoptotic pathway initiated by Aβ. In the present study, we provide evidence that the endocannabinoid system can stabilize lysosomes against Aβ-induced permeabilization and in turn sustain cell survival. We report that endocannabinoids stabilize lysosomes by preventing the Aβ-induced up-regulation of the tumor suppressor protein, p53, and its interaction with the lysosomal membrane. We also provide evidence that intracellular cannabinoid type 1 receptors play a role in stabilizing lysosomes against Aβ toxicity and thus highlight the functionality of these receptors. Given the deleterious effect of lysosomal membrane permeabilization on cell viability, stabilization of lysosomes with endocannabinoids may represent a novel mechanism by which these lipid modulators confer neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923768      PMCID: PMC2992287          DOI: 10.1074/jbc.M110.162040

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

Review 1.  The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review.

Authors:  R A Nixon; A M Cataldo; P M Mathews
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

3.  Lysosomal membrane permeabilization during apoptosis--involvement of Bax?

Authors:  Katarina Kågedal; Ann-Charlotte Johansson; Uno Johansson; Gerd Heimlich; Karin Roberg; Nancy S Wang; Juliane M Jürgensmeier; Karin Ollinger
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

4.  Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury.

Authors:  Susan M Knoblach; Daniel A Alroy; Maria Nikolaeva; Ibolja Cernak; Bogdan A Stoica; Alan I Faden
Journal:  J Cereb Blood Flow Metab       Date:  2004-10       Impact factor: 6.200

5.  Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system.

Authors:  A M Cataldo; J L Barnett; S A Berman; J Li; S Quarless; S Bursztajn; C Lippa; R A Nixon
Journal:  Neuron       Date:  1995-03       Impact factor: 17.173

6.  Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.

Authors:  Qing Liu; Manjunatha Bhat; Wayne D Bowen; Jianguo Cheng
Journal:  J Pharmacol Exp Ther       Date:  2009-09-14       Impact factor: 4.030

Review 7.  Oxidative metabolism of endocannabinoids by COX-2.

Authors:  Kevin R Kozak; Jeffery J Prusakiewicz; Lawrence J Marnett
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

8.  Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model.

Authors:  B Chen; K Bromley-Brits; G He; F Cai; X Zhang; W Song
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

9.  Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis.

Authors:  A J Yang; D Chandswangbhuvana; L Margol; C G Glabe
Journal:  J Neurosci Res       Date:  1998-06-15       Impact factor: 4.164

10.  Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study.

Authors:  Jeremy Koppel; Heather Bradshaw; Terry E Goldberg; Houman Khalili; Philippe Marambaud; Michael J Walker; Miguel Pazos; Marc L Gordon; Erica Christen; Peter Davies
Journal:  Lipids Health Dis       Date:  2009-01-14       Impact factor: 3.876

View more
  16 in total

Review 1.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

2.  The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged rats.

Authors:  Riffat Tanveer; Aoife Gowran; Janis Noonan; Sinead E Keating; Andrew G Bowie; Veronica A Campbell
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

3.  Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway.

Authors:  Wei-jia Wang; Yuan Wang; Hang-zi Chen; Yong-zhen Xing; Feng-wei Li; Qian Zhang; Bo Zhou; Hong-kui Zhang; Jie Zhang; Xue-li Bian; Li Li; Yuan Liu; Bi-xing Zhao; Yan Chen; Rong Wu; An-zhong Li; Lu-ming Yao; Ping Chen; Yi Zhang; Xu-yang Tian; Friedrich Beermann; Mian Wu; Jiahuai Han; Pei-qiang Huang; Tianwei Lin; Qiao Wu
Journal:  Nat Chem Biol       Date:  2013-12-08       Impact factor: 15.040

Review 4.  Endocannabinoid signalling and the deteriorating brain.

Authors:  Vincenzo Di Marzo; Nephi Stella; Andreas Zimmer
Journal:  Nat Rev Neurosci       Date:  2015-01       Impact factor: 34.870

5.  Analysis of the Impact of CD200 on Phagocytosis.

Authors:  Anthony Lyons; Aedín M Minogue; Raasay S Jones; Orla Fitzpatrick; Janis Noonan; Veronica A Campbell; Marina A Lynch
Journal:  Mol Neurobiol       Date:  2016-11-09       Impact factor: 5.590

6.  β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors.

Authors:  Cristina Benito; Rosa María Tolón; Ana Isabel Castillo; Lourdes Ruiz-Valdepeñas; José Antonio Martínez-Orgado; Francisco Javier Fernández-Sánchez; Carmen Vázquez; Benjamin F Cravatt; Julián Romero
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 7.  The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Authors:  Martin E Cooper; Simon E Regnell
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

8.  Endocannabinoids in nervous system health and disease: the big picture in a nutshell.

Authors:  Stephen D Skaper; Vincenzo Di Marzo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 9.  The endocannabinoid system in normal and pathological brain ageing.

Authors:  Andras Bilkei-Gorzo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

10.  The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation.

Authors:  Niamh Murphy; Thelma R Cowley; Christoph W Blau; Colin N Dempsey; Janis Noonan; Aoife Gowran; Riffat Tanveer; Weredeselam M Olango; David P Finn; Veronica A Campbell; Marina A Lynch
Journal:  J Neuroinflammation       Date:  2012-04-26       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.